Natera (NasdaqGS:NTRA) announced a strategic expansion of its Board of Directors with the appointment of Monica Bertagnolli. This decision occurred against a backdrop of significant market volatility, ...

What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 5.2% in the afternoon session after stocks ...

RBC Capital analyst Conor McNamara initiated coverage of Natera (NTRA) with an Outperform rating and $251 price target The firm says Natera is ...

Genetic testing company Natera (NASDAQ:NTRA). reported Q4 CY2024 results , with sales up 53% year on year to $476.1 million.

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the ...

Natera has a twelve month low of $83.13 and a twelve month high of $183.00. The stock has a 50-day simple moving average of $165.61 and a two-hundred day simple moving average of $148.09.

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish ...

BTIG analyst Mark Massaro maintained a Buy rating on Natera (NTRA – Research Report) today and set a price target of $190.00. The company’s ...

Feb 21 - Medical diagnostics company Guardant Health (GH.O), opens new tab has sued rival Natera (NTRA.O), opens new tab in California federal court for allegedly stealing trade secrets related to ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the HEROES clinical trial. HEROES is a multi-center ...